This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. CHO Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.017. CHO Pharma's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is NT$0.00.
As of today (2025-04-25), CHO Pharma's share price is NT$42.30. CHO Pharma's Median PS Value is NT$0.00. Therefore, CHO Pharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for CHO Pharma's Median PS Value or its related term are showing as below:
ROCO:6586's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
CHO Pharma Median PS Value Historical Data
The historical data trend for CHO Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CHO Pharma's Median PS Value
For the Biotechnology subindustry, CHO Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where CHO Pharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CHO Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma (ROCO:6586) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
CHO Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
42.30
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma Median PS Value Related Terms
Thank you for viewing the detailed overview of CHO Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6586 has been successfully added to your 